Protagonist Therapeutics To Join S&P SmallCap 600, Effective Prior To Opening Of Trading On July 3
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics (PTGX) will join the S&P SmallCap 600, replacing Encore Wire (WIRE) effective prior to the opening of trading on July 3. Encore Wire is being acquired by Prysmian SpA, pending final conditions.

June 27, 2024 | 9:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Protagonist Therapeutics will join the S&P SmallCap 600, which could increase its visibility and attract more investors.
Joining the S&P SmallCap 600 can increase a company's visibility and attract more institutional investors, potentially leading to a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Encore Wire will be replaced by Protagonist Therapeutics in the S&P SmallCap 600 due to its acquisition by Prysmian SpA.
The acquisition by Prysmian SpA and subsequent removal from the S&P SmallCap 600 is a neutral event for Encore Wire's stock in the short term as the acquisition terms are already priced in.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 100